Evidence map›Paper›PMID 39331289›Full record

ArticleAnnals of surgical oncology2024

The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer.

Mahtab Vasigh, Ahmed Mohamed, Lisa Jacobs, Julie Lange, Melissa Camp, Bonnie Sun, Pamela Wright, Maureen O'Donnell, Hanh-Tam Tran, Olutayo Sogunro and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mahtab VasighDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Ahmed MohamedDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Lisa JacobsDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Julie LangeDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Melissa CampDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Bonnie SunDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Pamela WrightDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Maureen O'DonnellDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Hanh-Tam TranDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Olutayo SogunroDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Mehran HabibiDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Fabian JohnstonDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA.
David EuhusDepartment of Surgical Oncology, Johns Hopkins Medical Institute, Baltimore, MD, USA. deuhus1@jhmi.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast-conserving surgery is often discouraged in BRCA gene carriers with early onset breast cancer. The genetic variant carrier breast cancers are more likely to be multifocal or multicentric (MFMC). PATIENTS AND

methodThis retrospective study includes newly diagnosed patients with breast cancer undergoing genetic testing between 2010 and 2021 within the Johns Hopkins Regional Health System. After excluding patients who received neoadjuvant chemotherapy or stage IV breast cancers, patients were divided into two groups: those who tested positive for a variant recognized by the National Comprehensive Cancer Network as predisposing the patient to breast cancer (ATM, BRCA1, BRCA2, CHEK2, NF1, PALB2, RAD51C, RAD51D, and TP53) and those who tested negative. Pathologic features of the tumors were compared, focusing on evidence for MFMC disease, defined as more than one malignant foci more than 5 mm apart.

resultsAmong the 282 eligible cases, 69 (24%) were positive for a genetic variant. The variant carriers were younger at diagnosis (p < 0.001), more likely to have invasive ductal carcinoma (p = 0.03), more likely to have undergone mastectomy (p = 0.03), and more likely to have a grade 3 cancer (p = 0.003). Variant carriers were not more likely to have MFMC disease (28% vs. 22%, p = 0.4). A positive genetic variant was not a predictor of MFMC within the entire cohort [odds ratio (OR):1.3, 95% confidence interval (CI) 0.6-2.6, p = 0.5).

conclusionGenetic variant carrier cancers are not more likely to be MCMF than sporadic cancers.

Indexed as

Breast NeoplasmsGenetic Predisposition to DiseaseAdultAgedBiomarkers, TumorCarcinoma, Ductal, BreastFemaleFollow-Up StudiesGenetic VariationHumansMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorBRCA1BRCA2Breast cancer-associated genetic variantsMultifocal multicentric breast cancer

Identifiers

PMID39331289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.